Cardiovascular

SGLT2 inhibitors in heart failure management

Clinical Overview and When to Suspect SGLT2 Inhibitor Candidacy in Heart Failure

— Any symptomatic HF (NYHA II–IV) regardless of EF

— Recently hospitalized for ADHF (start before discharge, per SOLOIST-WHF/EMPULSE)

— T2DM with established ASCVD or high CV risk (primary prevention of HF)

— CKD with albuminuria (DAPA-CKD, EMPA-KIDNEY)

— Natriuresis/osmotic diuresis → preload reduction

— Improved myocardial energetics (ketone utilization)

— Reduced cardiac fibrosis, sympathetic tone, epicardial adipose

— Tubuloglomerular feedback restoration → renoprotection

Step 3 management: On a Step 3 CCS case of stable HFrEF on ACEi + beta-blocker + furosemide with persistent symptoms, the next-best step is frequently add an SGLT2 inhibitor and an MRA — not uptitrate the loop diuretic. Both reduce mortality; loops do not.

Board pearl: Benefit emerges within weeks (DAPA-HF showed separation by day 28), making early initiation — including during the index HF hospitalization once euvolemic and hemodynamically stable — a high-yield exam answer.

SGLT2 inhibitors (gliflozins) — dapagliflozin, empagliflozin, ertugliflozin, canagliflozin, bexagliflozin — are now foundational guideline-directed medical therapy (GDMT) for heart failure across the entire ejection fraction spectrum.

Originally developed as antihyperglycemics, landmark trials (DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DELIVER, SOLOIST-WHF) demonstrated mortality and HF-hospitalization benefit independent of diabetes status.

2022 AHA/ACC/HFSA guidelines give a Class I recommendation for SGLT2i in HFrEF (LVEF ≤40%) as one of the "four pillars" alongside ARNI/ACEi/ARB, evidence-based beta-blocker, and MRA.

2023 focused update gives Class 2a for HFmrEF (LVEF 41–49%) and HFpEF (LVEF ≥50%).

When to suspect a patient should be on one:

Mechanism is multimodal, not glycemic:

Presentation Patterns and Key History

— 62-year-old with HFrEF (EF 30%), on lisinopril, carvedilol, spironolactone, furosemide

— NYHA II symptoms, BP 118/72, eGFR 45, K 4.4

— Diabetic or non-diabetic — doesn't matter

— Correct next step: add dapagliflozin or empagliflozin

— EF and HF phenotype (HFrEF, HFmrEF, HFpEF — all benefit)

— Hospitalizations in past year (worsening HF subgroup has largest absolute benefit)

— Diabetes status and A1c (affects glycemic monitoring, not eligibility)

— Volume status (avoid initiating during active decompensation with aggressive IV diuresis)

— Recurrent UTI or genital mycotic infections (relative caution)

— History of DKA, type 1 DM, pancreatectomy (avoid)

— Recent surgery planned (hold 3–4 days preop)

— Foot ulcers, prior amputation (canagliflozin caution — CANVAS signal)

— Malaise, nausea, abdominal pain, tachypnea → euglycemic DKA

— Severe perineal pain out of proportion → Fournier gangrene

— Polyuria, dehydration, orthostasis in elderly → volume depletion

Key distinction: A patient with HFpEF and obesity who is non-diabetic still gets an SGLT2i. Pre-2021 board answers may have steered toward "diuretic only for HFpEF" — that is now outdated. EMPEROR-Preserved and DELIVER changed practice; the test reflects this.

Board pearl: A common distractor is "start metformin first" in a diabetic with HF — but in HF + T2DM, SGLT2i carries Class I HF indication and should be prioritized; metformin remains safe but does not reduce HF events.

Step 3 vignettes rarely test "what is HF" — they test which patient already has HF and is missing an SGLT2i from their regimen, or who just got started and is now having a complication.

Classic candidate vignette:

Key history to extract:

Symptoms that should make you suspect a complication of an SGLT2i already prescribed:

Physical Exam Findings and Hemodynamic Assessment Before Initiation

— Volume status: JVP, lung exam, peripheral edema, weight trend

— Perfusion: narrow pulse pressure, cool extremities, mottling → "cold" profile is a contraindication to initiation

— Orthostatic vitals: especially in elderly or those on multiple antihypertensives

— BP floor: SBP ≥95 mmHg generally required; <90 mmHg → hold

— Genitourinary exam if recurrent infections suspected

— Foot exam in diabetics — ulcers, ischemia, prior amputation

— Warm & dry (A): ideal — initiate or continue

— Warm & wet (B): diurese first, then start SGLT2i before discharge (EMPULSE supports inpatient initiation)

— Cold & wet (C): stabilize hemodynamics, inotropes if needed; defer SGLT2i

— Cold & dry (L): address perfusion first

— Mild weight loss (1–2 kg) from natriuresis

— Possible drop in SBP 3–5 mmHg

— Reduced edema, lower diuretic requirement (often can decrease furosemide dose by 25–50%)

CCS pearl: On a CCS case admitted with ADHF, sequence is: IV loop diuretic → daily weights, strict I/Os, BMP q24h → once near-euvolemic and off IV diuretic for ≥24h with SBP ≥100 → initiate SGLT2i + ensure ARNI, BB, MRA on board → discharge with 7–14 day follow-up.

Board pearl: A drop in eGFR of up to 30% in the first 2–4 weeks is expected and benign — reflects hemodynamic effect on tubuloglomerular feedback, not injury. Do not discontinue for this finding alone.

SGLT2i are not rescue drugs for acutely congested patients — but they can and should be started once a hospitalized HF patient is stabilized.

Pre-initiation exam priorities:

Hemodynamic profiles (Stevenson) and SGLT2i decision:

Expected exam changes after initiation (1–4 weeks):

Diagnostic Workup — Initial Labs and Pre-Initiation Testing

— BMP: Na, K, BUN, creatinine, eGFR, bicarbonate (low HCO₃ raises DKA concern)

— Glucose and A1c (identifies T2DM, screens for undiagnosed DM)

— Urinalysis: baseline glycosuria, ketones, infection screen

— NT-proBNP or BNP: establish HF baseline for follow-up

— CBC if not recent (hematocrit may rise slightly on therapy — a benign hemoconcentration effect linked to outcomes)

— LFTs if hepatic disease suspected

— TTE within the last 6–12 months to confirm EF and phenotype (drives strength of recommendation)

— ECG baseline — no specific SGLT2i ECG concerns, but standard HF workup

— Dapagliflozin: initiate if eGFR ≥25 mL/min/1.73 m²; continue until dialysis

— Empagliflozin: initiate if eGFR ≥20; continue until dialysis

— Canagliflozin/ertugliflozin: higher thresholds, less commonly used for HF

— Type 1 diabetes (DKA risk)

— Prior DKA on SGLT2i

— Pregnancy/lactation

— ESRD on dialysis (no benefit, increased risk)

— Severe hypersensitivity

Step 3 management: A patient with HFrEF and eGFR 22 mL/min — empagliflozin is the correct choice; dapagliflozin's label requires ≥25. Know the specific thresholds; question banks exploit them.

Board pearl: Do not check ketones routinely at initiation in non-diabetics. But in a symptomatic patient on SGLT2i with nausea/abdominal pain and normal glucose, send beta-hydroxybutyrate and ABG — euglycemic DKA is missed when clinicians anchor on glucose <250.

Before starting an SGLT2 inhibitor in a HF patient, obtain a focused baseline panel — not an exhaustive workup, but enough to flag contraindications and establish trend lines.

Required baseline labs:

Imaging/functional:

eGFR thresholds (current FDA + guideline):

Absolute contraindications:

Diagnostic Workup — Confirming HF Phenotype to Justify SGLT2i Use

— TTE is the cornerstone — LVEF, diastolic indices (E/e′, LA volume index), valvular pathology, RV function, pulmonary pressures

— NT-proBNP: age-adjusted cutoffs; >125 pg/mL outpatient, >300 pg/mL acute setting supports HF

— Cardiac MRI: when infiltrative disease suspected (amyloid, sarcoid) — these patients still benefit but may need disease-specific therapy too

— Right heart catheterization: rarely needed for SGLT2i decision; used when phenotype is ambiguous (HFpEF vs noncardiac dyspnea) — wedge >15 mmHg confirms

— Stress testing/coronary angiography: to evaluate ischemic etiology — important because revascularization in viable ischemic HF complements GDMT

— HFrEF (≤40%): DAPA-HF, EMPEROR-Reduced — 25–26% reduction in CV death/HF hosp

— HFmrEF (41–49%) & HFpEF (≥50%): EMPEROR-Preserved, DELIVER — ~20% reduction in composite, driven by HF hospitalizations

— Acute decompensated HF: SOLOIST-WHF (sotagliflozin), EMPULSE (empagliflozin) — benefit when started in-hospital

Key distinction: HFpEF benefit was historically elusive — ACEi, ARB, beta-blockers all failed to show mortality reduction. SGLT2i and MRAs are the only drug classes with positive HFpEF outcome data; ARNI (PARAGON-HF) showed a near-miss with possible benefit at lower EF ranges.

Board pearl: A patient with "HFpEF" and unexplained LV thickening, low-voltage ECG, and bilateral carpal tunnel history — screen for transthyretin amyloidosis before defaulting to standard HFpEF therapy. SGLT2i is still appropriate adjunctively.

SGLT2i benefit spans all HF phenotypes, but board questions often hinge on confirming the phenotype to justify the management choice and exclude mimics.

Confirmatory steps:

Phenotype-specific evidence:

Amyloid cardiomyopathy: Still consider SGLT2i, but diurese cautiously — these patients are preload-dependent.

Risk Stratification and Sequencing Within GDMT

1. ARNI (sacubitril/valsartan) — preferred over ACEi/ARB; Class I

2. Evidence-based beta-blocker — carvedilol, metoprolol succinate, or bisoprolol

3. MRA — spironolactone or eplerenone

4. SGLT2 inhibitor — dapagliflozin or empagliflozin

— Start ARNI + beta-blocker + SGLT2i early (low doses)

— Add MRA once K and renal function confirmed stable

— Uptitrate ARNI and beta-blocker over 2–4 weeks

— No titration required — one-and-done dosing (dapagliflozin 10 mg, empagliflozin 10 mg daily)

— No hyperkalemia risk (unlike MRA, ARNI)

— Minimal hypotension if euvolemic

— Modest natriuresis allows down-titration of loop diuretic

— MAGGIC score, Seattle HF Model

— Persistently elevated NT-proBNP despite GDMT → consider advanced therapy referral

Step 3 management: When a CCS HFrEF patient is on 3 pillars but missing SGLT2i, add it before uptitrating existing meds further. Adding a missing class beats squeezing more dose from an existing one.

Board pearl: STRONG-HF showed that high-intensity early uptitration with frequent follow-up (within 1–2 weeks of discharge) reduced 180-day death/readmission by ~34%. Schedule the follow-up visit.

Old paradigm: sequential uptitration over months — ACEi first, then beta-blocker, then MRA, then SGLT2i. Each titrated to max before adding the next.

Current paradigm (STRONG-HF, 2022 guidelines): simultaneous or rapid sequential initiation of all four pillars at low doses, then uptitrate. This achieves mortality benefit faster.

Four pillars of HFrEF:

Suggested initiation order (within days to weeks):

Why SGLT2i goes in early:

Risk stratification tools for prognosis (not directly for SGLT2i choice but commonly asked):

Pharmacotherapy — Drug Selection, Dosing, and Drug Interactions

— Dapagliflozin (Farxiga): 10 mg PO daily; HFrEF, HFpEF, CKD, T2DM

— Empagliflozin (Jardiance): 10 mg PO daily; HFrEF, HFpEF, CKD, T2DM, post-MI (EMPACT-MI)

— Canagliflozin (Invokana): 100–300 mg; T2DM/CKD; amputation and fracture signal (CANVAS) limits HF preference

— Ertugliflozin (Steglatro): weakest CV evidence (VERTIS-CV neutral for CV death)

— Bexagliflozin: newer, T2DM indication

— No titration required

— Take in morning to minimize nocturia

— Can be taken with or without food

— No renal dose adjustment within approved eGFR ranges

— Loop diuretics: synergistic natriuresis → anticipate dose reduction (often 25–50%) within first 2 weeks to avoid volume depletion

— Insulin and sulfonylureas: increase hypoglycemia risk → reduce doses ~20% in diabetics

— ACEi/ARB/ARNI: additive BP-lowering; monitor orthostasis

— Rifampin (strong UGT inducer): reduces canagliflozin exposure

— Digoxin: canagliflozin increases levels modestly

— Hold 3 days before surgery (4 days for ertugliflozin) per FDA 2020 update — reduces perioperative euglycemic DKA risk

— Hold during acute illness with poor PO intake, vomiting, or dehydration ("sick day rules")

— Hold during prolonged fasting (>24h) or very low-carb/ketogenic diets

Step 3 management: Patient on dapagliflozin scheduled for elective cholecystectomy in 5 days — hold dapagliflozin 3 days prior, resume when eating normally postoperatively and hemodynamically stable.

Board pearl: When you start an SGLT2i in a euvolemic patient on furosemide 80 mg daily, decrease the furosemide to 40 mg and reassess weight/symptoms in 1–2 weeks to prevent symptomatic volume depletion and AKI.

Two agents with HF labeling in the US:

Others (less HF-focused):

Dosing pearls:

Drug interactions:

Hold instructions:

Expanded Pharmacology — Mechanism, Class Effects, and Combination Strategy

— SGLT2 cotransporter in proximal tubule reabsorbs ~90% of filtered glucose; inhibition causes glycosuria (~50–80 g/day) and natriuresis

— Restores tubuloglomerular feedback via increased macula densa Na delivery → afferent arteriolar constriction → reduced intraglomerular pressure → long-term renoprotection

— Cardiac effects: shift toward ketone/fatty acid oxidation (more energy-efficient), reduced cardiac fibrosis, decreased sympathetic activity, reduced epicardial adipose inflammation

— Hematocrit rise: likely via increased erythropoietin from restored renal cortical oxygenation — mediation analyses suggest this drives ~50% of mortality benefit

— ↓ HF hospitalization (~30%)

— ↓ CV death (HFrEF, T2DM)

— ↓ progression of CKD, ↓ albuminuria

— Modest BP reduction (3–5 mmHg)

— Modest weight loss (2–3 kg)

— A1c reduction 0.5–0.8% (diminishes at lower eGFR)

— + ARNI: complementary — ARNI augments natriuretic peptides; SGLT2i provides natriuresis and energetics

— + MRA: additive on outcomes; monitor K (SGLT2i may slightly lower K, partially offsetting MRA hyperkalemia)

— + Loop diuretic: synergistic — facilitates decongestion

— + Finerenone (nonsteroidal MRA): emerging combo for CKD/HF + T2DM (FIDELIO, FIGARO)

— + GLP-1 RA (semaglutide, tirzepatide): STEP-HFpEF showed semaglutide improves HFpEF symptoms in obesity — complementary, not redundant

Key distinction: SGLT2i are not primarily glucose-lowering drugs in HF — A1c reduction is modest and falls with declining eGFR, yet cardiorenal benefit persists at low eGFR. The mechanism is hemodynamic/metabolic, not glycemic.

Board pearl: When the question asks "which therapy reduces HF hospitalization in HFpEF" — the answer is SGLT2 inhibitor (and increasingly MRA). ACEi, ARB, beta-blockers do not.

Mechanism in depth:

Class effects (consistent across cardiorenal agents):

Combination with other HF therapies:

Special Populations — Elderly and Renal/Hepatic Impairment

— Benefit preserved across age strata in DAPA-HF, EMPEROR, DELIVER

— Higher absolute risk reduction because baseline event rate is higher

— Watch for: orthostatic hypotension, volume depletion, falls, recurrent UTIs

— Start at standard dose; reduce concomitant loop diuretic by 25–50% prophylactically

— Reassess BP, orthostatics, BUN/Cr at 1–2 weeks

— Dapagliflozin: initiate eGFR ≥25, continue until dialysis (DAPA-CKD)

— Empagliflozin: initiate eGFR ≥20, continue until dialysis (EMPA-KIDNEY)

— Glucose-lowering effect attenuates below eGFR 45, but cardiorenal benefit persists

— Expected early eGFR dip of 3–5 (up to 30% acceptable) — do not discontinue; recheck in 2–4 weeks

— Discontinue on initiation of dialysis

— SGLT2i are associated with lower long-term AKI risk despite the initial eGFR dip

— During an acute AKI episode (volume depletion, contrast, sepsis), hold temporarily and resume when stable

— Mild-moderate (Child-Pugh A/B): no dose adjustment

— Severe (Child-Pugh C): limited data — dapagliflozin start at 5 mg; generally avoid empagliflozin if marked dysfunction

— Common geriatric scenario: HF + CKD + T2DM + HTN on 10+ meds — SGLT2i often allows reduction of loop diuretic and insulin doses, improving the regimen rather than complicating it

Step 3 management: 82-year-old with HFrEF, eGFR 28, on furosemide 80 mg, lisinopril, carvedilol, spironolactone. Next step: add empagliflozin 10 mg daily, reduce furosemide to 40 mg, recheck BMP and orthostatics in 1–2 weeks.

Board pearl: Do not be fooled by "eGFR dropped from 45 to 35 after starting dapagliflozin" — this is expected hemodynamic effect, not nephrotoxicity. Continue therapy.

Elderly (≥75 years):

CKD:

AKI:

Hepatic impairment:

Polypharmacy considerations:

Special Populations — Pregnancy, T1DM, Post-MI, and Other Subgroups

— Contraindicated — animal data show renal developmental toxicity in 2nd/3rd trimester

— Counsel reproductive-age women on contraception

— If pregnancy planned or detected: discontinue immediately and substitute pregnancy-safe HF therapy (hydralazine/nitrates if needed; avoid ACEi/ARB/ARNI/SGLT2i)

— Lactation: avoid

— Avoid — markedly elevated DKA risk

— Off-label use exists in tightly selected adults with T1DM, but not for Step 3 answers

— EMPACT-MI (2024): empagliflozin in post-MI patients at high HF risk did not reduce a composite of HF hospitalization or all-cause death significantly, though HF hospitalization alone trended favorably

— DAPA-MI: similar mixed results

— Current practice: start SGLT2i post-MI if LVEF ≤40% or signs of HF; less compelling otherwise

— SGLT2i is first-line add-on regardless of A1c control

— Reduces HF hospitalization, MACE, and renal progression simultaneously

— STEP-HFpEF: semaglutide improved HFpEF symptoms and exercise capacity in BMI ≥30

— Combine SGLT2i + GLP-1 RA in obese diabetic HFpEF

— Not approved for pediatric HF; emerging data only

— Continue SGLT2i while on GDMT; discontinue when transitioning to inotrope-dependent end-stage care

— Cardio-oncology context (anthracycline cardiomyopathy): SGLT2i increasingly used; small trials encouraging

Key distinction: Pregnancy is a hard contraindication for SGLT2i, ACEi, ARB, ARNI, and MRA. The pregnancy-safe HF regimen relies on hydralazine + nitrates ± beta-blocker (metoprolol/labetalol) + loop diuretic as needed.

Board pearl: A 28-year-old woman with peripartum cardiomyopathy 6 weeks postpartum, not breastfeeding, EF 30% — she can start SGLT2i, ARNI, BB, MRA. Lactation is the modifier, not the postpartum state itself.

Pregnancy:

Type 1 diabetes:

Post-MI / acute coronary syndrome:

HF with concomitant T2DM:

HF with obesity:

Pediatrics:

Transplant/LVAD candidates:

HIV, oncology patients:

Complications and Adverse Effects

— Genital mycotic infections (vulvovaginal candidiasis, balanitis): most common AE, ~3–5x baseline rate; usually mild, treat with topical antifungal, do not stop drug

— UTIs: modest increase; treat as usual; recurrent severe UTI is a reason to reconsider

— Fournier gangrene (necrotizing fasciitis of perineum): rare but life-threatening — FDA black box warning; emergent surgical debridement + broad-spectrum antibiotics + discontinue drug permanently

— Glucose often <250 mg/dL — easily missed

— Triggers: surgery, fasting, infection, low-carb diet, alcohol, insulin reduction

— Workup: anion gap, beta-hydroxybutyrate, ABG, lactate

— Management: stop SGLT2i, IV fluids, IV insulin with dextrose, electrolyte repletion (same as DKA but must give dextrose to prevent hypoglycemia since glucose is already near-normal)

— Higher risk in elderly, on loop diuretics, low baseline BP

— Mitigation: down-titrate loop diuretic at initiation, monitor weights, orthostatics

— Hold 3 days preop (4 for ertugliflozin)

— CANVAS signal; not replicated with dapa/empa

— Avoid canagliflozin in patients with PAD, prior amputation, neuropathic ulcers

— Mild LDL increase (clinically insignificant)

— Transient hematocrit rise — generally benign

— Rare hypersensitivity, angioedema

CCS pearl: A patient on dapagliflozin presents 3 days post-op with nausea, tachypnea, glucose 180, bicarbonate 12, anion gap 22, ketones positive — diagnosis is euglycemic DKA. Order: stop SGLT2i, IV NS, insulin drip with D5 cosadministered, q1h glucose, q2–4h electrolytes, address trigger.

Board pearl: Perineal pain + fever + erythema in an SGLT2i user is Fournier gangrene until proven otherwise — surgical emergency.

Genitourinary infections:

Euglycemic DKA:

Volume depletion / hypotension / AKI:

Ketoacidosis in perioperative period:

Bone fracture and amputation (canagliflozin-specific):

Other:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Euglycemic DKA: admit; ICU if pH <7.1, severe AKI, or hemodynamic instability

— Fournier gangrene: surgical emergency — urology/general surgery STAT, ICU level monitoring, broad-spectrum antibiotics (piperacillin-tazobactam + clindamycin + vancomycin), source control

— Severe volume depletion with AKI: hold drug, IV fluids, hold diuretics, hospitalize if Cr doubled or oliguria

— Severe symptomatic hypoglycemia in diabetics on insulin/SU + SGLT2i: reverse, reassess regimen

— NYHA IV symptoms despite optimized GDMT → cardiology referral for advanced therapies

— Persistent NT-proBNP elevation, recurrent hospitalizations, hypotension limiting GDMT → consider LVAD, transplant evaluation, palliative inotropes

— Cardiogenic shock: ICU; SGLT2i is held; restart once stabilized

— Cardiology: refractory symptoms, need for advanced HF therapies, complex device decisions

— Nephrology: rapid eGFR decline, persistent albuminuria, near-dialysis

— Endocrinology: recurrent DKA, T1DM consideration, complex glycemic control

— Infectious disease/surgery: Fournier gangrene

— Surgical consult within minutes for suspected Fournier gangrene

— ICU transfer for DKA with hemodynamic instability

— Cardiology consult within 24h for new ADHF admission

CCS pearl: On a CCS case of a patient on empagliflozin with abdominal pain, glucose 160, bicarbonate 14 — first orders: ABG, beta-hydroxybutyrate, BMP, lactate, UA. Don't anchor on "glucose is normal, can't be DKA."

Board pearl: SGLT2i is held, not stopped permanently, for most acute illnesses — resume after recovery unless DKA or Fournier (then permanent discontinuation).

Most SGLT2i-related issues are managed outpatient, but specific triggers require escalation.

Emergency department / inpatient triage:

HF-related escalation (independent of SGLT2i but on CCS cases):

Specialist consultation triggers:

CCS-specific timing:

Key Differentials — Other HF Therapies and Sequencing Confusions

— Both Class I in HFrEF

— ARNI replaces ACEi/ARB; SGLT2i is added independently

— Both should be on; not either/or

— ARNI requires 36h washout from ACEi (angioedema risk)

— Both Class I in HFrEF, Class 2a in HFpEF

— MRA monitoring: K and Cr at 1 week, 1 month, then q3–6 months

— Hold MRA if K >5.5 or Cr rises >30%

— SGLT2i tends to lower K slightly, complementing MRA

— Loops: symptomatic therapy, no mortality benefit

— SGLT2i: mortality + symptom benefit

— Both used; expect to decrease loop dose when adding SGLT2i

— Only carvedilol, metoprolol succinate, bisoprolol are evidence-based for HFrEF

— Hold uptitration if HR <55 or symptomatic hypotension

— Niche: HFrEF in sinus rhythm, HR ≥70 despite max BB

— Class 2a, used after the four pillars

— VICTORIA: high-risk HFrEF post-decompensation; modest event reduction

— Class 2b add-on

— Symptom relief only; no mortality benefit; narrow therapeutic window

Key distinction: ARNI is substituted for ACEi/ARB (one RAAS-blocker only). SGLT2i and MRA are each added as separate pillars. A patient should be on ARNI + BB + MRA + SGLT2i simultaneously when tolerated.

Board pearl: If a question shows a HFrEF patient stable on ACEi + BB + MRA + furosemide and asks the next step, the answer hierarchy is: (1) switch ACEi → ARNI, (2) add SGLT2i. Both are correct; if only one is offered, pick that one.

Step 3 questions often test whether you can pick the right drug class among other GDMT options for a specific scenario.

ARNI (sacubitril-valsartan) vs SGLT2i:

MRA (spironolactone/eplerenone) vs SGLT2i:

Loop diuretics vs SGLT2i:

Beta-blocker selection:

Ivabradine:

Vericiguat (sGC stimulator):

Digoxin:

Key Differentials — Non-HF Conditions That SGLT2i Also Treats (and Confuses)

— SGLT2i are preferred add-on after metformin in T2DM with ASCVD, HF, or CKD (ADA Standards of Care)

— A1c reduction modest (0.5–0.8%); use is driven by cardiorenal benefit, not glycemic

— DAPA-CKD (dapagliflozin): non-diabetic and diabetic CKD with eGFR 25–75 + albuminuria — reduced kidney failure, CV death

— EMPA-KIDNEY (empagliflozin): broader population including non-albuminuric CKD — reduced kidney disease progression

— KDIGO 2022/2024: SGLT2i recommended for CKD + T2DM and for non-diabetic CKD with albuminuria

— Mixed evidence (EMPACT-MI, DAPA-MI) — use if LV dysfunction develops

— Empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS) reduce MACE in T2DM with ASCVD

— Emerging benefit; not yet a labeled indication

— Right HF from pulmonary disease/cor pulmonale: treat underlying pulmonary process; SGLT2i benefit less defined

— Constrictive pericarditis: surgical, not pharmacologic

— High-output HF (thyrotoxicosis, AV fistula, anemia): treat the cause

— HOCM: mavacamten, not SGLT2i, is disease-modifying

Key distinction: SGLT2i benefit in HFpEF is real; SGLT2i benefit in isolated right HF from pulmonary hypertension is not established. Always identify the dominant HF substrate.

Board pearl: A non-diabetic patient with eGFR 40, urine ACR 350 mg/g, and no HF still benefits from an SGLT2i for renoprotection (DAPA-CKD, EMPA-KIDNEY). This is a frequent Step 3 trap where examinees withhold the drug because the patient "doesn't have diabetes or HF."

SGLT2 inhibitors span multiple indications, and Step 3 questions test recognition of overlap.

Type 2 diabetes (with or without HF):

Chronic kidney disease (with or without diabetes):

Post-myocardial infarction:

Atherosclerotic cardiovascular disease (T2DM):

MASLD/MASH (formerly NAFLD/NASH):

Conditions to distinguish from "needs SGLT2i":

Secondary Prevention, Discharge Medications, and Long-Term Plan

— ARNI (or ACEi/ARB if intolerant) — initiate before discharge once stable; 36h washout if switching from ACEi

— Evidence-based beta-blocker — start low, continue

— MRA — if K <5.0 and eGFR >30

— SGLT2i — dapagliflozin 10 mg or empagliflozin 10 mg — initiate before discharge

— Loop diuretic — lowest effective dose

— Hydralazine + nitrate — add in self-identified Black patients with persistent NYHA III–IV (A-HeFT)

— Anticoagulation if AF; statin per ASCVD risk

— ICD if EF ≤35% despite 3 months optimized GDMT, life expectancy >1 year

— CRT if EF ≤35%, LBBB ≥150 ms, NYHA II–IV on GDMT

— Influenza annually

— Pneumococcal per ACIP

— COVID-19 boosters

— RSV in age ≥60

— Sodium <2–3 g/day (less strict than older 2 g for euvolemic patients per recent SODIUM-HF data)

— Fluid restriction ~1.5–2 L/day if hyponatremic or congestion-prone

— Weight monitoring daily — alert physician for >2 lb overnight or 5 lb/week gain

— Cardiac rehabilitation referral — Class I in stable HF

— Genital hygiene (reduce mycotic infection)

— Sick-day rules (hold if vomiting, severe dehydration, prolonged fasting)

— Hold 3 days preop

— Symptoms of DKA even if glucose normal

Step 3 management: Discharge orders for ADHF should include: GDMT (4 pillars), loop diuretic, 7–14 day follow-up appointment, weight log, sodium/fluid counseling, cardiac rehab referral, vaccinations updated.

Board pearl: In-hospital initiation of SGLT2i increases the chance the patient is actually on it at 90 days — a major quality metric. Don't defer to "outpatient clinic to decide."

An ADHF hospitalization is a sentinel event — 30-day readmission ~25%, 1-year mortality 20–30%. Discharge optimization is critical.

Discharge GDMT checklist (HFrEF):

Devices to consider longitudinally:

Vaccinations (secondary prevention of HF exacerbations):

Lifestyle counseling:

SGLT2i-specific counseling:

Follow-Up, Monitoring Parameters, and Counseling

— Phone call or visit within 48–72 hours (transitional care)

— Clinic visit within 7–14 days (STRONG-HF–aligned)

— Re-evaluate weight, BP, orthostatics, BMP, symptoms

— Uptitrate GDMT toward target doses over 2–6 weeks

— Repeat TTE at 3–6 months if EF improvement expected (recovery may justify continued GDMT regardless)

— BMP at 1–2 weeks, then at 1 month, then q3–6 months

— Expected: eGFR drop 3–5 mL/min (up to 30% acceptable, transient)

— Mild rise in hematocrit (1–3%) — benign

— Monitor for symptomatic volume depletion, especially in elderly

— Mycotic infection screen at each visit (ask, don't only inspect)

— Foot exam in diabetics

— A1c q3 months if diabetic

— Useful for prognosis, less so for titration in HFpEF

— Substantial decrease (>30%) at 4–8 weeks associated with better outcomes

— Class I recommendation; insurance-covered with HF diagnosis

— 36 sessions over 12 weeks

— Improves QoL, exercise capacity, modest mortality benefit

— Medication adherence — 4 pillars is a lot; use combination pills, pillboxes

— Self-monitoring — daily weights, symptom diary

— Sick-day rules — hold SGLT2i and diuretics during gastroenteritis with dehydration

— Activity — no restriction in stable HF; encourage rehab

— Diet — moderate Na restriction; avoid alcohol if cardiomyopathy etiology

— Vaccinations — annual flu, pneumococcal, RSV, COVID

Step 3 management: At the 2-week post-discharge visit, eGFR has dropped from 55 → 45 on a newly added SGLT2i. Continue the drug, recheck in 2 weeks — this is expected. Do not discontinue.

Board pearl: A patient who gains 4 lbs in 3 days at home — double the loop diuretic for 48–72h per home action plan, contact clinic. This is the "yellow zone" intervention that prevents readmission.

Post-discharge HF follow-up cadence:

SGLT2i-specific monitoring:

NT-proBNP trending:

Cardiac rehab:

Patient counseling pillars:

Ethical, Legal, and Patient Safety Considerations

— Discuss SGLT2i's mortality benefit (NNT ~21 for CV death/HF hosp over 18 months in DAPA-HF) and key risks (DKA, mycotic infection, volume depletion, Fournier gangrene)

— Document discussion, especially in elderly with limited life expectancy where benefit timeline matters

— For patients on multiple medications, discuss polypharmacy trade-offs and simplification (e.g., reducing loop diuretic)

— Brand-only in US — $500–600/month list price; copays variable

— Patient assistance programs available; advocate via social work

— Avoid the safety hazard of prescribing without confirming affordability — non-adherence due to cost is a common transition-of-care failure

— Medication reconciliation at every transition — admission, transfer, discharge

— Sick-day rules documented in writing — when to hold SGLT2i, loops

— Surgical hold instructions communicated to surgical team and patient — failure to hold 3 days preop is a sentinel-event-class error driving perioperative euglycemic DKA

— Clear follow-up appointment scheduled before discharge, not "call to schedule"

— SGLT2i underutilized in Black, Hispanic, low-income, and women patients with HF (registry data) — actively counter prescribing bias

— Use teach-back for sick-day rules, weight monitoring

— In NYHA IV refractory HF transitioning to comfort-focused care, deprescribe SGLT2i and other GDMT when symptom burden outweighs benefit

— Discuss goals of care, ICD deactivation

— Adverse events (DKA, Fournier) → MedWatch

— Document baseline EF, NT-proBNP, GDMT contraindications

Step 3 management: Patient scheduled for elective hip replacement is on dapagliflozin — document the hold instruction 3 days preop in the preop note and the discharge summary; communicate with surgical and anesthesia teams. This single step prevents a preventable harm.

Board pearl: Failure to initiate SGLT2i in an eligible HFrEF patient is increasingly framed as a quality and safety gap, not a discretionary choice — analogous to omitting aspirin post-MI.

Informed consent and shared decision-making:

Cost and access:

Transition-of-care safety (high-yield Step 3):

Health literacy and disparities:

End-of-life / palliative considerations:

Reporting and documentation:

High-Yield Associations and Rapid-Fire Clinical Facts

— HFrEF: DAPA-HF (dapa), EMPEROR-Reduced (empa)

— HFpEF/HFmrEF: EMPEROR-Preserved (empa), DELIVER (dapa)

— ADHF (in-hospital initiation): SOLOIST-WHF (sota), EMPULSE (empa)

— CKD: DAPA-CKD, EMPA-KIDNEY, CREDENCE (cana)

— T2DM CV outcomes: EMPA-REG, CANVAS, DECLARE-TIMI 58

— Post-MI: EMPACT-MI, DAPA-MI

— eGFR floor: dapa 25, empa 20

— Hold preop: 3 days (4 for ertugliflozin)

— Expected eGFR dip: up to 30%, acceptable

— Typical A1c reduction: 0.5–0.8%

— BP reduction: 3–5 mmHg

— Weight reduction: 2–3 kg

— NNT (DAPA-HF, 18 mo): ~21 for CV death/HF hosp

Board pearl: "Class I in HFrEF, Class 2a in HFmrEF/HFpEF" — know these guideline class strengths verbatim; vignettes pivot on them.

Key distinction: SGLT2 inhibitors reduce mortality; loop diuretics do not. When the question pits "increase furosemide" vs "add dapagliflozin" in a symptomatic patient, choose the SGLT2i.

Trials by phenotype (memorize):

One-number facts:

Four pillars of HFrEF: ARNI, BB, MRA, SGLT2i

Black box / boxed warnings: Fournier gangrene; lower-limb amputation (canagliflozin)

Contraindications: T1DM, prior DKA, pregnancy, dialysis, hypersensitivity

Hold during: acute illness with dehydration, prolonged fasting, ketogenic diet, perioperative period

Synergies: SGLT2i + loop (reduce loop dose), SGLT2i + MRA (K balance), SGLT2i + GLP-1 RA (in obese diabetic HFpEF)

Mechanism mnemonic — "G-N-K-H": Glucosuria, Natriuresis, Ketone use, Hematocrit rise

Common test trap: Withholding SGLT2i in non-diabetic HF — wrong; benefit is independent of diabetes

Another trap: Stopping SGLT2i for early eGFR dip — wrong; expected and benign

Vaccinations in HF: flu, pneumococcal, COVID, RSV

Discharge bundle: 4 pillars + loop + 7–14 day follow-up + weight log + rehab referral

Board Question Stem Patterns

— 60M, HFrEF EF 30%, on lisinopril/carvedilol/spironolactone/furosemide, NYHA II

— Answer: Add dapagliflozin (or switch lisinopril to sacubitril-valsartan if offered)

— 70F, EF 55%, dyspnea on exertion, NT-proBNP 600, on lisinopril and HCTZ

— Answer: Add empagliflozin (Class 2a HFpEF; EMPEROR-Preserved/DELIVER)

— Patient with eGFR 22 needs SGLT2i — empagliflozin (≥20), not dapagliflozin (≥25)

— Post-op day 2, on SGLT2i, nausea, glucose 170, bicarb 12, anion gap 22 — diagnose euglycemic DKA; treat with IV fluids + insulin + dextrose, stop SGLT2i

— Cr rose from 1.1 to 1.4 two weeks after starting dapa — continue, recheck in 2 weeks

— Elective surgery in 5 days on dapagliflozin — hold 3 days preop

— Diabetic on canagliflozin with perineal pain, fever, erythema — surgical emergency, broad-spectrum antibiotics, stop SGLT2i permanently

— ADHF, day 3, off IV diuretic for 24h, euvolemic, SBP 110 — initiate SGLT2i before discharge

— Reproductive-age woman with HFrEF planning pregnancy — discontinue SGLT2i, ACEi, ARB, ARNI, MRA; use hydralazine/nitrate + BB

— Starting SGLT2i in patient on furosemide 80 mg — reduce furosemide ~25–50% to prevent volume depletion

— Patient with gastroenteritis vomiting on dapagliflozin — hold SGLT2i and diuretics until rehydrated

— Non-diabetic eGFR 40, ACR 400 — start SGLT2i for renoprotection

Step 3 management: When in doubt on a HF vignette, ask "is this patient missing one of the four pillars?" — if yes, that's almost always the answer.

Board pearl: When a stem shows GDMT but no SGLT2i, that absence is the test — the correct answer is to add it.

Pattern 1 — The missing pillar:

Pattern 2 — The non-diabetic HFpEF patient:

Pattern 3 — The renal threshold trap:

Pattern 4 — Euglycemic DKA recognition:

Pattern 5 — Expected eGFR dip:

Pattern 6 — Preoperative hold:

Pattern 7 — Fournier gangrene:

Pattern 8 — In-hospital initiation:

Pattern 9 — Pregnancy:

Pattern 10 — Diuretic adjustment:

Pattern 11 — Sick-day rules:

Pattern 12 — CKD without diabetes:

One-Line Recap

SGLT2 inhibitors (dapagliflozin, empagliflozin) are Class I guideline-directed therapy for HFrEF and Class 2a for HFmrEF/HFpEF — reducing mortality and HF hospitalization across the EF spectrum, irrespective of diabetes status — and should be initiated early (often before hospital discharge), at fixed dose, alongside the other three pillars (ARNI/ACEi/ARB, evidence-based beta-blocker, MRA), with anticipatory loop diuretic dose reduction, perioperative 3-day hold, and vigilance for euglycemic DKA and genitourinary infection.

Board pearl: The single most common Step 3 HF mistake on exam is failing to add an SGLT2i to a "well-managed" patient on ACEi + BB + MRA + furosemide — that patient is not optimized.

Key distinction: Loop diuretics relieve symptoms; SGLT2 inhibitors, ARNI, evidence-based beta-blockers, and MRAs prolong life. Choose mortality-modifying therapy whenever a question offers both.

Step 3 management: If a CCS HF case ends without the patient on an SGLT2i (in absence of a true contraindication), the case is incomplete — add it before final disposition.

Four pillars: ARNI + evidence-based BB + MRA + SGLT2i — initiate simultaneously when feasible (STRONG-HF), not sequentially over months.

Eligibility floors: dapagliflozin eGFR ≥25, empagliflozin eGFR ≥20; continue until dialysis; an early eGFR dip up to 30% is expected and benign.

Safety triad to memorize: (1) Euglycemic DKA — treat with insulin + dextrose, stop drug; (2) Fournier gangrene — surgical emergency, permanent discontinuation; (3) Volume depletion — preempt by reducing concomitant loop diuretic 25–50% at initiation.

Discharge bundle after ADHF: all four pillars + lowest effective loop dose + 7–14 day follow-up + daily weights + sick-day rules + cardiac rehab referral + vaccinations.